What Researchers Did
Researchers compared keloid tissue and skin from three groups of 9 people each: keloid patients, keloid patients who received hyperbaric oxygen therapy (HBOT), and people with normal skin.
What They Found
In a small clinical study of 27 people in three groups of 9, keloid patients who received HBOT had lower levels of several tissue markers linked to epithelial-to-mesenchymal transition (EMT) than keloid patients who did not. Blood flow in the keloid was measured with a laser Doppler flowmeter before HBOT and surgery, and it was significantly reduced after HBOT. Compared with the keloid group, the HBOT group had lower levels of vimentin, fibronectin, VEGF and HIF-1α. Levels of E-cadherin and ZO-1 were significantly higher, and their mRNA levels also rose after HBOT. The authors wrote that HBOT may be an effective therapy against the EMT phenomenon in keloid patients.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study was small, with 9 patients per group, and it reported tissue and blood-flow measurements rather than clinical outcomes such as scar change, so it cannot show that HBOT helps keloid patients in practice.